发明名称 Integrin expression inhibitors
摘要 The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. <CHEM> In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, -CH=CH- or - (CR<4b>R<5b>)m<b>- (wherein R<4b> and R<5b> are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and m<b> means an integer of 1 or 2); R<1> means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or -CO-NH-; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively. <IMAGE>
申请公布号 AU2886701(A) 申请公布日期 2001.08.14
申请号 AU20010028867 申请日期 2001.02.01
申请人 EISAI CO. LTD. 发明人 TOSHIAKI WAKABAYASHI;YASUHIRO FUNAHASHI;NAOKO HATA;TARO SEMBA;YUJI YAMAMOTO;TORU HANEDA;TAKASHI OWA;AKIHIKO TSURUOKA;JUN-ICHI KAMATA;TADASHI OKABE;KEIKO TAKAHASHI;KAZUMASA NARA;SHINICHI HAMAOKA;NORIHIRO UEDA
分类号 A61K45/06;A61K31/00;A61K31/145;A61K31/18;A61K31/404;A61K31/4045;A61K31/438;A61K31/4439;A61K31/506;A61P7/02;A61P9/10;A61P17/06;A61P19/02;A61P19/10;A61P35/00;A61P35/04;C07D209/08;C07D209/12;C07D209/30;C07D209/34;C07D209/42;C07D215/38;C07D217/02;C07D217/22;C07D217/24;C07D311/04;C07D401/12;C07D403/12;C07D405/12;C07D409/12;C07D409/14;C07D411/12;C07D417/12;C07D471/04 主分类号 A61K45/06
代理机构 代理人
主权项
地址